Abstract
This 3-part Urologic Cancer Supplement reviews research presented at the 2012 Canadian Urological Association meeting which took place at Banff, Alberta, in June. Alan So, MD, FRCSC, examines three abstracts which compared surgeon performance in radical nephrectomy and prostatectomy against factors such as surgical volume, fellowship training, and teaching hospital affiliation. Bobby Shayegan, MD, FRCSC, Shawn Dason, MD, and Christopher Allard, MD, discuss the changing evidence and attitudes among Canadian physicians regarding testosterone suppression in prostate cancer, asking how low we need to aim in order to maximize the delay before progression to castrate-resistant prostate cancer. Finally, Peter Black, MD, FRCSC, considers some Canadian data on results achieved in muscle-invasive bladder cancer with gemcitabine and cisplatin (gem-cis), a therapy often preferred over MVAC due to lower toxicity, but with a question mark hanging over its efficacy.

Keywords
Renal cell carcinoma, kidney cancer, prostate cancer, bladder cancer, urothelial carcinoma, nephrectomy, prostatectomy, chemotherapy, androgen deprivation, testosterone.